ICU MEDICAL INC annual report, FY2017

Vollständiges Dokument

ICU Medical, Inc. — 2017 Form 10-K

Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing; quarterly figures are included below where relevant. ICU Medical expanded substantially after acquiring Pfizer’s Hospira Infusion Systems (HIS) business on February 3, 2017, adding infusion pumps, IV solutions, sets, and distribution operations. The company also acquired Fannin and Medical Australia.

Financial performance and liquidity

  • Revenue: $1.293 billion, versus $379.4 million in 2016. The increase primarily reflects the HIS acquisition; 2017 includes about eleven months of acquired-business revenue. Revenue included $522.0 million from IV Solutions, $365.6 million from Infusion Consumables, $290.2 million from Infusion Systems, and $50.0 million from Critical Care.
  • Profit and margins: Gross profit was $426.1 million and gross margin was 33.0%, down from 53.1% in 2016. ICU reported an operating loss of $15.1 million, but net income of $68.6 million, or $3.29 diluted EPS. Results included a $70.9 million HIS bargain-purchase gain and a $17.4 million income-tax benefit. Without the bargain gain, reported pretax income would have been substantially lower.
  • Costs and unusual items: Restructuring, strategic transaction, and integration expenses totaled $78.0 million, including $59.2 million of transaction and integration costs. A $66.3 million acquisition-date inventory fair-value step-up also affected HIS pro forma earnings and gross margin. ICU cited HIS’s historically lower margins, purchase-accounting inventory charges, and temporary inventory-reduction effects as drivers of lower gross margin.
  • Fourth quarter: Revenue was $370.1 million, gross profit was $137.5 million, and net income was $49.7 million, or $2.33 diluted EPS. In Q4 2016, revenue was $95.7 million and net income was $9.5 million.
  • Cash flow: Operating cash flow was $154.4 million, compared with $89.9 million in 2016. Capital expenditures were $74.5 million; the filing attributes a significant working-capital cash benefit to a $181.7 million inventory reduction, largely from planned management of acquired inventory.
  • Liquidity and debt: Cash, cash equivalents, and investment securities totaled $300.1 million at year-end, down from $445.1 million. Working capital was $654.4 million. ICU had no borrowings under its $150 million five-year revolving facility and had repaid the $75 million Pfizer seller note. The company stated existing cash and expected operating cash flow should fund operations for the next twelve months.
  • Capital needs: Management estimated 2018 capital expenditures of $80–$90 million. The credit facility includes maximum leverage and minimum fixed-charge coverage covenants; ICU reported compliance at year-end.

Changes versus the prior year

  • The HIS acquisition transformed the business mix: IV Solutions and Infusion Systems, absent as reported product lines in 2016, represented 40% and 23% of 2017 revenue, respectively. Infusion Consumables fell from 86% to 28% of the total largely because of the expanded revenue base.
  • Reported 2017 net income rose from $63.1 million to $68.6 million, while diluted EPS declined from $3.66 to $3.29 as weighted-average shares increased, including shares issued to Pfizer. Operating income shifted from $82.9 million to a $15.1 million loss, reflecting acquisition-related expenses and the changed business mix.
  • SG&A increased to $304.0 million from $89.4 million, and R&D increased to $51.3 million from $13.0 million, primarily due to the acquired business and post-acquisition operations.

Outlook, risks, and contingencies

  • Management expects to invest in manufacturing capacity, customer-placed infusion products, and IT, but did not provide revenue or earnings guidance. It identified HIS integration, customer retention, realization of expected synergies, and transition-service dependence on Pfizer as significant execution risks.
  • Pfizer may receive up to $225 million in contingent cash consideration if combined-company performance targets are met through 2019. The year-end earn-out liability was $27.0 million, including an $8.0 million 2017 fair-value increase.
  • ICU disclosed putative antitrust class actions concerning U.S. IV saline pricing and a U.S. Department of Justice antitrust investigation, along with a New York Attorney General subpoena concerning the HIS IV-solutions business. The matters involve indemnification claims between ICU and Pfizer under the acquisition agreement; outcomes and exposure are not established in the filing.
  • Accrued liabilities included an $11.8 million product field-action accrual. The filing does not provide a clear description of the underlying action in the supplied text.
  • Other risks include sole- or limited-source materials, dependence on key products and major customer/distributor relationships, manufacturing concentration, regulatory and product-liability exposure, healthcare pricing and reimbursement pressure, international credit and currency risks, and patent competition. A 10% euro exchange-rate movement was estimated to affect relevant net balance-sheet assets by about $8.7 million; ICU did not hedge its euro exposure.
  • The December 2017 U.S. tax law introduced a 21% federal corporate rate and other changes. ICU recorded provisional tax expense related to deferred-tax remeasurement and deemed repatriation, and said it was still assessing provisions that could affect future tax rates.

Key facts for investors to verify

  • Whether post-acquisition integration delivers the expected operating benefits and improves gross margins, and how much of revenue and earnings is attributable to acquired HIS operations.
  • The nature, status, potential financial exposure, and Pfizer indemnification coverage for the saline antitrust litigation, government investigation, and accrued product field action.
  • The assumptions behind the $70.9 million bargain-purchase gain, $27.0 million earn-out liability, and potential additional payment of up to $225 million.
  • Cash conversion and working-capital trends, particularly whether the large 2017 inventory reduction is repeatable, alongside planned 2018 capital spending.
  • The effect of the Tax Act and acquisition-related controls integration. Auditors issued unqualified opinions, but management excluded HIS from its internal-control assessment; HIS represented 82% of consolidated 2017 revenue and 49% of year-end assets.